GGrantIndex
← Leaderboards

Krishna H Murthy

University Of Alabama At Birmingham

Google Scholar ↗PubMed ↗ORCID ↗
$5,770,792
Attributed
$5,770,792
Total exposure
35
Grants
12
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $859.1K · FY2005–07
$1M$750K$500K$250K$0
'05
'06
'07

Funding mix

By agency

NIH$5,770,792 · 35

By mechanism

R01$2,985,764 · 2
P51$2,785,028 · 33

Top collaborators

No co-investigators on record.

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Animal Colony”

Research focus

Animal ColonyPrimatesInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseProtein Structure FunctionSourceHepatitis C VirusFundingUnited States National Institutes Of HealthResearch PersonnelResourcesGrantVirus ProteinSerine ProteinasesSite Directed MutagenesisGene MutationDengue VirusEnzyme ActivityProtease InhibitorPan GenusAnimalsPan TroglodytesInfectionHepatitis

Grant awards (46)

CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$387,808
P51 · FY2007 · RR · contact PI
Study of Interactions of VCP with Complement Components$274,972
R01 · FY2007 · AI · contact PI
IMMUNOGENETHERAPY OF CHRONIC HCV CARRIER CHIMPANZEES$70,937
P51 · FY2007 · RR · contact PI
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$70,936
P51 · FY2007 · RR · contact PI
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$27,999
P51 · FY2007 · RR · contact PI
IMMUNOGENICITY OF HIV CANDIDATE VACCINES IN BABOONS$21,677
P51 · FY2007 · RR · contact PI
NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS$4,795
P51 · FY2007 · RR · contact PI
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$313,469
P51 · FY2006 · RR · contact PI
Study of Interactions of VCP with Complement Components$283,042
R01 · FY2006 · AI · contact PI
NEUTRALIZING ANTIBODY INDUCTION IN BABOONS$82,202
P51 · FY2006 · RR · contact PI
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$65,749
P51 · FY2006 · RR · contact PI
SYNTHETIC IGE PEPTIDE VACCINE FOR IMMUNOTHERAPY OF ALLERGY$33,890
P51 · FY2006 · RR · contact PI
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$12,717
P51 · FY2006 · RR · contact PI
Study of Interactions of VCP with Complement Components$290,000
R01 · FY2005 · AI
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$262,385
P51 · FY2005 · RR
IMMUNOGENICITY AND EFFICACY OF A NOVEL CANDIDATE VACCINE FOR AIDS$74,268
P51 · FY2005 · RR
NEUTRALIZING ANTIBODY INDUCTION IN BABOONS$68,823
P51 · FY2005 · RR
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$53,036
P51 · FY2005 · RR
SYNTHETIC IGE PEPTIDE VACCINE FOR IMMUNOTHERAPY OF ALLERGY$27,323
P51 · FY2005 · RR
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$10,285
P51 · FY2005 · RR
CELL-MEDIATED IMMUNE RESPONSE TO RSV IN BABOONS$5,506
P51 · FY2005 · RR
SAFETY AND EFFICACY OF A LHRH VACCINE IN BABOONS$2,078
P51 · FY2005 · RR
STRUCTURE BASED ANALYSIS OF DENGUE VIRUS SERINE PROTEASE$304,375
R01 · FY2004 · AI
Study of Interactions of VCP with Complement Components$290,000
R01 · FY2004 · AI
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$227,733
P51 · FY2004 · RR
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$165,826
P51 · FY2004 · RR
HIV-1 ADENOVIRUS-BASED VACCINE STUDY IN CHIMPANZEES$62,393
P51 · FY2004 · RR
CATEGORY B MAO: IMMUNOGENICITY IF AD-HIVNEF RECOMBINANT VIRUSES$5,684
P51 · FY2004 · RR
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$5,516
P51 · FY2004 · RR
IMMUNOTHERAPY OF CHRONIC HBV INFECTION IN CHIMPANZEES$5,516
P51 · FY2004 · RR
TITRATION OF HCV STRAIN STOCK IN VIVO IN CHIMPANZEES$5,516
P51 · FY2004 · RR
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH$423,458
P51 · FY2003 · RR
Study of Interactions of VCP with Complement Components$315,000
R01 · FY2003 · AI
STRUCTURE BASED ANALYSIS OF DENGUE VIRUS SERINE PROTEASE$304,375
R01 · FY2003 · AI
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE$95,742
P51 · FY2003 · RR
HIV-1 DNA VACCINE STUDIES IN BABOONS$49,020
P51 · FY2003 · RR
CATEGORY B MAO: IMMUNOGENICITY IF AD-HIVNEF RECOMBINANT VIRUSES$49,020
P51 · FY2003 · RR
HIV-1 ADENOVIRUS-BASED VACCINE STUDY IN CHIMPANZEES$49,020
P51 · FY2003 · RR
PSORALEN/UV INACTIVATION OF HEPATITIS B AND C VIRUS$31,929
P51 · FY2003 · RR
VACCINES IN PREGNANT FEMALES &THEIR OFFSPRING$3,193
P51 · FY2003 · RR
IMMUNOTHERAPY OF CHRONIC HBV INFECTION IN CHIMPANZEES$3,193
P51 · FY2003 · RR
TITRATION OF HCV STRAIN STOCK IN VIVO IN CHIMPANZEES$3,193
P51 · FY2003 · RR
DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE$3,193
P51 · FY2003 · RR
STRUCTURE BASED ANALYSIS OF DENGUE VIRUS SERINE PROTEASE$304,375
R01 · FY2002 · AI
STRUCTURE BASED ANALYSIS OF DENGUE VIRUS SERINE PROTEASE$304,375
R01 · FY2001 · AI
STRUCTURE BASED ANALYSIS OF DENGUE VIRUS SERINE PROTEASE$315,250
R01 · FY2000 · AI